Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results

About this update from Knight Therapeutics, Inc.

[{"type":"text","content":"Knight Therapeutics Reports Fourth Quarter and Year-End 2024 ResultsReports record-high revenues since inception\n\n\n\n MONTREAL, March 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (\"Knight\" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.\n \n\n\n 2024 Highlights\n \n\n\n\n Financial results\n \n\n\n\n Revenues were $371,304, an increase of $43,105 or 13% over the prior year. The increase was driven by the growth of our key promoted products, the impact of hyperinflation in Argentina, partly offset by declines of our mature products and the depreciation of select LATAM currencies.\n \n\n Gross margin was $174,405 or 47% of revenues compared to $152,652 or 47% of revenues in prior year.\n \n\n Operating income was $7,397 compared to an operating loss of $2,890 in prior year.\n \n\n Net income was $4,332, compared to a net loss $16,835 in prior year.\n \n\n Earnings per share was $0.04, compared to a loss per share of $0.16 in prior year.\n \n\n Cash inflow from operations was $36,280, an increase of $341 or 1% over prior year.\n \n\n\n\n Non-GAAP measures\n \n\n\n\n Adjusted Revenues\n \n 1\n \n were $365,412, an increase of $22,274 or 6% or an increase of $29,439 or 9% on a constant currency\n \n 1\n \n basis, driven by the growth of our key promoted products partly offset by declines of our mature products.\n \n\n Adjusted Gross margin\n \n 1\n \n was $173,496 or 47% of Adjusted Revenues\n \n 1\n \n compared to $166,190 or 48% of Adjusted Revenues\n \n 1\n \n in prior year.\n \n\n Adjusted EBITDA\n \n 1\n \n was $57,783, a decrease of $2,292 or 4% over prior year.\n \n\n Adjusted EBITDA per share\n \n 1\n \n was $0.58, a decrease of $0.01 or 2% over prior year driven by investments on our new launches and pipeline offset by the impact of the common shares purchased through the NCIB.\n \n\n\n\n Corporate developments\n \n\n\n\n Launched a NCIB in July 2024 to purchase up to 5,312,846 common shares of the Company over the next 12 months.\n \n\n Purchased 1,619,167 common shares through Knight’s NCIB at an average price of $5.53 for ag...

More updates from Knight Therapeutics, Inc.